Literature DB >> 11161598

Survival of intrastriatal xenografts of ventral mesencephalic dopamine neurons from MHC-deficient mice to adult rats.

W M Duan1, M Westerman, T Flores, W C Low.   

Abstract

Previous studies of neural xenografts have used immunosuppressive agents to prevent graft rejection. In the present study we have examined the survival of mouse dopamine neurons lacking either MHC class I or MHC class II molecules transplanted into rat brains and the host immune and inflammatory responses against the xenografts. Survival of neural grafts was immunocytochemically determined at 4 days, 2 weeks, and 6 weeks after transplantation by counting tyrosine hydroxylase (TH)-positive cells in the graft areas. In addition, the host immune and inflammatory responses against neural xenografts were evaluated by semiquantitatively rating MHC class I and class II antigen expression, accumulation of macrophages and activated microglia, and infiltration of CD4- and CD8-positive T-lymphocytes. For the negative controls, the mean number of TH-positive cells in rats that received wild-type mouse tissue progressively decreased at various time periods following transplantation. In contrast, intrastriatal grafting of either MHC class I or MHC class II antigen-depleted neural xenografts resulted in a prolonged survival and were comparable to cyclosporin A-treated rats that had received wild-type mouse tissue. These results indicate that genetically modified donor tissue lacking MHC molecules can be used to prevent neural xenograft rejection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161598     DOI: 10.1006/exnr.2000.7537

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  3 in total

1.  Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.

Authors:  Anabel S de la Garza-Rodea; Marieke C Verweij; Hester Boersma; Ietje van der Velde-van Dijke; Antoine A F de Vries; Rob C Hoeben; Dirk W van Bekkum; Emmanuel J H J Wiertz; Shoshan Knaän-Shanzer
Journal:  PLoS One       Date:  2011-01-06       Impact factor: 3.240

Review 2.  The immunological challenges of cell transplantation for the treatment of Parkinson's disease.

Authors:  Amanda L Piquet; Kala Venkiteswaran; Neena I Marupudi; Matthew Berk; Thyagarajan Subramanian
Journal:  Brain Res Bull       Date:  2012-04-11       Impact factor: 4.077

Review 3.  Cell therapy for Parkinson's disease is coming of age: current challenges and future prospects with a focus on immunomodulation.

Authors:  Shirley D Wenker; Fernando J Pitossi
Journal:  Gene Ther       Date:  2019-04-16       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.